Myriad Genetics Reports Fiscal Second-Quarter 2020 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/2/2026
- Wall St set to snap three-day losing streak as stocks reclaim some shine
- Oil rises 1%, as US-Iran strikes risk limiting already impaired supplies
- Dell again lifts annual forecasts as AI demand powers record results
- Could Apple’s foldable iPhone be a $14B opportunity? Morgan Stanley weighs in
- Uber stock gains 2% as tech giant cuts 3,300 jobs in major restructuring
- GoPro to merge with Starman Optical in $285M recapitalization deal
- GoPro (GPRO) Halted, News Pending
- Wall Street ends lower as higher yields, rising oil prices mark shaky start to September
- Crude Inventory Fell 4.5M Barrels Last Week - EIA
- TScan cuts 75% of workforce, pivots to solid tumor cell therapy
Myriad Genetics (MYGN) announces Mark Capone has resigned as President and CEO
February 6, 2020 4:14 PM ESTMyriad Genetics, Inc. (Myriad or the Company) (NASDAQ: MYGN), a leader in molecular diagnostics and precision medicine, announced today that R. Bryan Riggsbee, Chief Financial Officer, has been appointed Interim President and CEO effective immediately and will also continue to serve as Chief Financial Officer. Mark C. Capone has resigned as President and Chief Executive Officer and as a member of the Companys Board of Directors, effective immediately. Mr. Capone will remain available to the Company to assist in this transition.
As we position Myriad for its next phase of growth and... More
Myriad Genetics (MYGN) Misses Q2 EPS by 8c, Guidance Misses
February 6, 2020 4:13 PM ESTMyriad Genetics (NASDAQ: MYGN) reported Q2 EPS of $0.23, $0.08 worse than the analyst estimate of $0.31. Revenue for the quarter came in at $195.1 million versus the consensus estimate of $209.81 million.
GUIDANCE:
Myriad Genetics sees Q3 2020 EPS of $0.02, versus the consensus of $0.30. Myriad... More
